Background--Pregnant women with underlying heart disease (HD) are at increased risk for adverse maternal, obstetric, and neonatal outcomes.
H eart disease (HD) is a leading cause of maternal deaths in the United States and other developed countries. [1] [2] [3] HD in pregnancy represents a spectrum of etiologies, inclusive of cardiomyopathies, valvular HD (VHD), pulmonary hypertension (PH), and adult congenital HD (ACHD). Recent epidemiological data suggest that the prevalence of maternal HD during pregnancy is rising, [4] [5] [6] not only for those with ACHD but for those with acquired HD such as cardiomyopathy and PH. 7 Both acquired and ACHD predispose pregnant women and their offspring to a heightened risk of adverse events, particularly during labor and delivery. [8] [9] [10] However, an overwhelming majority of the data in the arena of fetal or neonatal outcomes in women with HD are centered on the outcomes of women with ACHD [11] [12] [13] [14] [15] [16] [17] [18] [19] and not on those with acquired HD such as cardiomyopathy, VHD, or PH, although these forms of HD are collectively more common. Comparative research in these areas is also lacking.
In this study, we sought to evaluate the maternal, obstetric, and neonatal outcomes of pregnant women with and without multiple forms of HD (cardiomyopathy, VHD, PH, ACHD) in a contemporary cohort of women admitted for delivery in New York State. Furthermore, we sought to identify the risk factors and predictors of adverse fetal/neonatal events in the offspring of women with all major forms of HD affecting women of childbearing potential.
Methods Data Source and Study Population
The Statewide Planning And Research Cooperative System (SPARCS) database from the New York State Department of Health was used to characterize maternal and fetal/neonatal outcomes from January 1, 2000, through December 31, 2014 ( Figure 1 ). The SPARCS data set allows for linking of maternal and fetal records through birth certificate data. Only singleton records with a linked baby's discharge number and observation number were used in our analysis because multiple births and women with >1 delivery during the study period could not be accurately linked. In addition, only women's earliest singleton deliveries during the study period were used in the analysis to avoid the possible confounding effect of multiple deliveries. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes to identify pregnancy, forms of HD, and complications were obtained (Table S1 ). Records containing predetermined diagnosis or procedure codes (Table S1 ) were treated as delivery records. Patients aged <18 years and those with missing information including unique patient identifiers were excluded. Records with the same unique patient identifier, date of birth, admission date, discharge date, and facility name were considered as pure duplications, and only one of such records was kept. Records showing multiple subtypes of cardiomyopathy (peripartum, hypertrophic, dilated) simultaneously were excluded (n=184). Institutional review board approval from Stony Brook University was obtained before obtaining the data and proceeding with analysis. The data set was analyzed retrospectively, and the informed consent requirement was waived.
Outcome Measures
Maternal major adverse cardiac events (MACE) were defined by ICD-9-CM codes as a composite of in-hospital death, cardiac arrest, acute myocardial infarction, heart failure, arrhythmia, cerebrovascular events, pulmonary embolism, arterial embolism, obstetric pulmonary embolism, and cardiac complications of anesthesia or other sedation in labor and delivery, cardiorespiratory failure or shock, dissection of the aorta, dissection of another artery, and respiratory failure (Table S1) . 6, 8, 20 Cardiac procedural and non-cardiac-associated procedural covariates were also recorded for patients with and without HD but not included in MACE. Non-MACE maternal outcomes included 30-day readmission rate, acute renal failure, length of stay, and total hospital charges. Obstetric outcomes included gestational diabetes mellitus, polyhydraminos, premature rupture of membranes, placental insufficiency, transient hypertension of pregnancy, 
Clinical Perspective
What Is New?
• In this study of delivery admissions in New York State over a 15-year period, pregnant women with multiple forms of cardiac disease including cardiomyopathy, valvular heart disease, adult congenital heart disease, and pulmonary hypertension experienced an increased risk of adverse maternal cardiac, obstetric, and fetal/neonatal events.
• Women with cardiomyopathy and pulmonary hypertension and their offspring had the worst overall outcomes.
What Are the Clinical Implications?
• This study highlights the neonatal risks for offspring in women with cardiac disease.
• These findings may guide risk assessment and monitoring decisions for pregnant women with cardiac disease and their offspring.
preeclampsia/eclampsia (all types), postpartum hemorrhage or infection, laceration, and antepartum hemorrhage. 
Results
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Prevalence of HD
Among the 2 284 044 women composing the study population, 3871 (0.2%) women had HD and 2 280 173 (99.8%) did not. Of the women with HD, 676 (17%) had cardiomyopathy, 1528 (40%) had VHD, 1367 had ACHD (35%), and 300 (8%) had PH ( Figure 2 ).
Patient Characteristics
Patient characteristics and demographics are described in Table 1 . Mothers with HD had greater tobacco dependence, obesity, and preexisting hypertension than mothers without HD. Women with HD were more likely to be delivered by a cesarean approach compared with the no-HD group, with most in the cardiomyopathy and PH groups. Assisted delivery was also more common in patients with versus without HD, particularly those with VHD or ACHD compared with cardiomyopathy or PH. Analysis of the small group of women excluded because of multiple deliveries (2.8% of total patient population analyzed) showed that the excluded patients were more likely to be older and more medically complicated (more likely to be obese, to use anticoagulants, to have diabetes mellitus and chronic hypertension)-factors that have previously been shown to be associated with MACE 8 and would have confounded our data were they included.
Maternal Cardiac Outcomes
Adverse maternal cardiac events during the hospitalization for delivery are listed in Table 2 and Figure 3A . Compared with women without HD, MACE was more common in women with HD, predominantly because of higher rates of arrhythmia, heart failure, and respiratory failure. MACE rates were highest in the cardiomyopathy and PH groups and lowest among women with ACHD. Both cardiac procedural interventions and non-cardia c-associated procedural covariates were more common in women with HD than No HD. Women with HD experienced longer length of stay, higher total hospital charges, higher rate of 30-day readmission, and higher rate of acute renal failure Arterial embolism Systemic arterial pressure monitoring 
Obstetric Complications
Obstetric complications were higher among women with versus without HD, with similar distributions among HD subtypes (Table S2) . Placental insufficiency, postpartum hemorrhage, postpartum infection, and venous complications were more common in mothers with HD.
Neonatal/Fetal Outcomes
Neonatal/fetal outcomes in the offspring of women with and without HD and 4 subtypes of HD are listed in Table 3 and Figure 3B and 3C. NACE was more common in offspring of women with than without HD and most common in offspring of women with cardiomyopathy and PH compared with those with VHD and ACHD. This was primarily due to increased rates of prematurity and small-for-gestational-age birth weight. Offspring of mothers with HD had an increased rate of fetal death, in-hospital death, intrauterine growth restriction, respiratory distress syndrome, intracranial or cerebral intraventricular hemorrhage, and CHD. Among women with HD, those with cardiomyopathy and PH had the highest rates of prematurity and small-for-gestationalage birth weight. Mothers with ACHD had the highest rate of CHD in their infants. Newborns of mothers with HD had longer length of stay, particularly the newborns of mothers with cardiomyopathy or PH. Normal birth weight >2500 g was less likely in newborns of mothers with HD (86.6% versus 94.2%). Very low birth weights of <1500 g occurred at highest rates in newborns of mothers with PH or cardiomyopathy.
Risk Factors Associated With NACE
All forms of HD were associated with an increased risk of incident NACE, with the highest risk in those with cardiomyopathy or PH. Offspring of women with VHD and ACHD also remained at risk, albeit relatively lower. Particularly among offspring of women with HD, the risk factors associated with adverse fetal/neonatal outcomes are listed on Table 4 . After multivariable adjustment, preeclampsia/eclampsia or severe preeclampsia, MACE, and obstetric complications were independently associated with NACE. Diabetes mellitus was associated with NACE in newborns.
Discussion
In this contemporary study of >2.2 million admissions for delivery in New York State during a 15-year period of time, women with HD including cardiomyopathy, ACHD, VHD, and PH experienced elevated rates of MACE, mainly related to arrhythmia and heart failure. Obstetric complications were more common in women with versus without HD. Women with HD experienced longer lengths of stay, higher total hospital charges, and a higher rate of 30-day readmission compared with those without HD. In this largest ever study of neonatal outcomes, neonatal complications were significantly increased in the offspring of pregnant women with Data are shown as n (%) except as noted. P values were based on ANOVA for continuous outcomes and the Pearson chi-squared test or Fisher exact test for categorical outcomes. ACHD indicates adult congenital heart disease; CHD, congenital heart disease; HD, heart disease; NACE, neonatal adverse clinical events; PH, pulmonary hypertension; VHD, valvular heart disease.
administrative data set demonstrated that although maternal cardiac complications were uncommon in the overall population, they were higher in those with complex ACHD. 15 Neonatal complications tended to follow a pattern similar to maternal and obstetric outcomes. They were highest in the offspring of cardiomyopathy and PH patients and lower in ACHD and VHD patients. NACE in the offspring of women with HD was slightly higher than past estimations of 5% to 7% in patients without any obstetric risk factors and lower than the previously reported projections of 27% to 33% in patients with obstetric risk factors. 12 CHD recurred in offspring of mothers with ACHD, with a prevalence similar to those in previous reports. 22 Notably, however, other populations of women with HD (VHD, cardiomyopathy, and PH) also gave birth to offspring with CHD above the approximate risk of 1% in the general population, a finding that requires further study. Notably, age, chronic hypertension, and obesity were not found to be risk factors for neonatal adverse events in multivariable analysis in this cohort of women with HD, contrary to published reports for the general population. [23] [24] [25] [26] Nevertheless, both age and obesity could have contributed to obstetric complications, either directly or indirectly, which were significantly related to NACE. The largest contributors to adverse neonatal outcomes were prematurity and small-for-gestational-age birth weight, common issues associated with prematurity. Although not captured in our study, prematurity and extremely low birth weight are known to pose increased risk for complications in early life through adulthood. Newborns and children can have respiratory issues, asthma, developmental delays, intestinal problems, infections, hearing loss, and retinopathy, among other issues. 27 We also found a significantly higher prevalence of preeclampsia/eclampsia or other hypertensive syndromes in women with HD compared with those without HD, a finding that we 6, 8, 9 and others have observed previously in various study populations. 15, 28 Preeclampsia alone, without the presence of overlapping HD, is a life-threatening disorder that, once evident clinically, can be cured only by delivery. Coupled with HD, the combination can be extremely high risk. In developed countries, surveillance through prenatal visits allows for early identification and intervention, which has been shown to be effective in reducing maternal mortality in women without HD. Although not well elucidated, reduced placental perfusion may cause preeclampsia, 28 which could be more common in women with HD than those without. It has been shown previously that, in women with HD, a decline in maternal cardiac output during pregnancy occurs, as well as abnormal umbilical artery Doppler flows, and that these factors independently predict neonatal complications. 29 These types of changes may result in placental ischemia, particularly in women with cardiomyopathy. 30 Moreover, in a recent report, offspring CHD was strongly associated with maternal preterm preeclampsia. 31 Women at high risk of preeclampsia, regardless of a history of HD, including those with a history of preeclampsia, multifetal gestation, chronic hypertension, diabetes mellitus, renal disease, and autoimmune diseases, are recommended to use low-dose aspirin after 12 weeks of gestation to reduce the risk of preeclampsia, preterm birth, and intrauterine growth restriction. 32, 33 Whether or not aspirin can be recommended in women with HD remains to be determined by future investigation. The effects of the complications of HD on the neonate make appropriate prenatal counseling critical for mothers with preexisting HD who are considering becoming pregnant. This type of counseling is complex and should be done by a comprehensive team of physicians, including primary care and specialists, to most effectively offer guidance and support to the patient. It requires expert advice on the assessment of maternal and fetal/neonatal risk of pregnancy, labor and delivery, timing of pregnancy, timing of pregnancy relative to future surgery or intervention, management during and after pregnancy, discontinuation of medications that may be teratogenic or continuation of medications that may prevent symptoms or complications during pregnancy, and proper knowledge of contraceptive choices appropriate for a patient's condition before the decision to become pregnant is made.
Study Limitations
Despite the large number of women with HD and their offspring captured in this study, these data should be interpreted within the context of several limitations. SPARCS is a New York State regional database, and although New York is a diverse state, these findings may not be generalizable to the entire United States. However, the data in this study appear to be similar to the findings from the National Inpatient Sample in terms of maternal risk. 6 Our study delineates a low (0.2%) incidence of HD; however, the analytical cohort is a subsection of the overall patient population captured in the SPARCS database. Consequently, because of the exclusion criteria applied, it may be possible that HD patient representation was selected from the overall population. Our study utilizes administrative and procedural codes (ICD-9-CM) and birth certificate linkage, instead of medical chart review. ICD-9 codes have imperfect sensitivity and specificity. 34 Undercoding or miscoding are possibilities, although this would be unlikely to bias the results, because even a small number of misclassifications would not have a sizable effect on summary estimates of >2.2 million women. Obstetric complication rates were high in our study population, even in the control group, potentially related to inclusion of multiple nonspecific codes. Moreover, the administrative nature of the data set does not allow verification of diagnoses; certain aspects of patient history, imaging data, laboratory values, medications, and long-term follow-up were not available for analysis. Moreover, the SPARCS data set did not allow reliable linking of mothers to neonates in certain instances (multiple births and repeat pregnancies), and many records had to be eliminated from the analysis because of concern about reliability issues. In addition, the inpatient nature of this data set does not allow us to capture the intensity or quality of care before and after the delivery hospitalization for mothers or neonates. Deaths, events, or hospitalizations after the index delivery hospitalization would not be included.
Conclusions
In this study of >2.2 million admissions for delivery in New York State during a 15-year period of time, women with HD including cardiomyopathy, ACHD, VHD, and PH experienced elevated rates of MACE, mainly related to arrhythmia and heart failure. Obstetric complications were more common in women with HD compared with those without HD. Neonatal complications were significantly increased in the offspring of pregnant women with HD, including fetal and in-hospital neonatal death, prematurity, small-for-gestational-age birth weight, respiratory distress syndrome, and CHD. Incident MACE and NACE were highest in women with cardiomyopathy and PH compared with those with VHD and ACHD. Eclampsia, preeclampsia, maternal MACE, obstetric complications, and diabetes mellitus were independently associated with a higher risk of incident NACE among women with HD. These results may guide monitoring decisions and risk assessment for pregnant women with HD and their offspring at the time of delivery. Given the higher rate of cardiac, obstetric, and neonatal complications, pregnant women with HD should be treated in a center with expertise in this area, with a multidisciplinary approach to labor and delivery. Prenatal counseling of fetal risks is warranted in women with HD. CM = cardiomyopathy, VHD = valvular heart disease, CHD = congenital heart disease, PH = pulmonary hypertension, NOS = not otherwise specified *P-values were based on Pearson's chi-squared test or Fisher's exact test.
